501 related articles for article (PubMed ID: 19464064)
1. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis.
Berger RM; Beghetti M; Galiè N; Gatzoulis MA; Granton J; Lauer A; Chiossi E; Landzberg M
Int J Cardiol; 2010 Oct; 144(3):373-8. PubMed ID: 19464064
[TBL] [Abstract][Full Text] [Related]
2. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
[TBL] [Abstract][Full Text] [Related]
3. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R
Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of sildenafil in Eisenmenger's syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study.
Garg N; Tripathy N; Sinha N
Cardiol Young; 2011 Dec; 21(6):631-8. PubMed ID: 21729508
[TBL] [Abstract][Full Text] [Related]
5. Repair of ventricular septal defect with Eisenmenger syndrome after bosentan treatment.
Hu L; Tan LH; Ye J
J Card Surg; 2014 May; 29(3):401-2. PubMed ID: 24612361
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease.
Zeng WJ; Lu XL; Xiong CM; Shan GL; Liu ZH; Ni XH; Gu Q; Zhao ZH; Li JJ; He JG;
Clin Cardiol; 2011 Aug; 34(8):513-8. PubMed ID: 21678455
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
[TBL] [Abstract][Full Text] [Related]
8. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.
Kotlyar E; Sy R; Keogh AM; Kermeen F; Macdonald PS; Hayward CS; McNeil KD; Celermajer DS
Cardiol Young; 2006 Jun; 16(3):268-74. PubMed ID: 16725066
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
[TBL] [Abstract][Full Text] [Related]
10. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
Beghetti M; Galiè N
J Am Coll Cardiol; 2009 Mar; 53(9):733-40. PubMed ID: 19245962
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
[TBL] [Abstract][Full Text] [Related]
12. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
[TBL] [Abstract][Full Text] [Related]
13. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease.
Engelfriet PM; Duffels MG; Möller T; Boersma E; Tijssen JG; Thaulow E; Gatzoulis MA; Mulder BJ
Heart; 2007 Jun; 93(6):682-7. PubMed ID: 17164490
[TBL] [Abstract][Full Text] [Related]
15. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
[TBL] [Abstract][Full Text] [Related]
16. Eisenmenger syndrome and atrial septal defect: nature or nurture?
Therrien J; Rambihar S; Newman B; Siminovitch K; Langleben D; Webb G; Granton J
Can J Cardiol; 2006 Nov; 22(13):1133-6. PubMed ID: 17102831
[TBL] [Abstract][Full Text] [Related]
17. Associated atrial septal defects increase perioperative morbidity after ventricular septal defect repair in infancy.
Knott-Craig CJ; Elkins RC; Ramakrishnan K; Hartnett DA; Lane MM; Overholt ED; Ward KE; Razook JR
Ann Thorac Surg; 1995 Mar; 59(3):573-8. PubMed ID: 7887692
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bosentan in adults with simple and complex Eisenmenger's syndrome.
Williams R; Houser L; Miner P; Aboulhosn J
Congenit Heart Dis; 2012; 7(1):12-5. PubMed ID: 22188797
[TBL] [Abstract][Full Text] [Related]
19. [Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].
Raposo-Sonnenfeld I; Otero-González I; Blanco-Aparicio M; Ferrer-Barba A; Medrano-López C
Rev Esp Cardiol; 2007 Apr; 60(4):366-72. PubMed ID: 17521545
[TBL] [Abstract][Full Text] [Related]
20. [The effect of an endothelin receptor antagonist in Eisenmenger syndrome: a single-center experience of 11 patients].
Poindron D; Godart F; Duhamel A; Richard A; Francart C; Brevière GM; Rey C
Arch Mal Coeur Vaiss; 2006 May; 99(5):457-62. PubMed ID: 16802735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
